argenx SE - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ARGX Nasdaq 2836 argenx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for argenx SE

Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More - May 29th, 2026 6:41 pm
Immune Thrombocytopenia Market Forecast Signals Steady Growth During the Forecast Period (2026-2036) Backed by Pipeline Advancements | DelveInsight - May 28th, 2026 8:01 am
argenx to Host Myositis R&D Webinar on June 23, 2026 - May 27th, 2026 11:00 pm
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - May 27th, 2026 9:08 am
Vyvgart Label Expansion And New CEO Put argenx Execution In Focus - May 27th, 2026 1:04 am
argenx to Present at Upcoming Investor Conferences - May 26th, 2026 11:00 pm
Evercore ISI Raises its Price Target on argenx (ARGX) - May 22nd, 2026 4:59 am
Pemphigus Vulgaris Market Analysis Report 2026-2036, Profiles of F. Hoffmann La Roche, Argenx, Sanofi, Syntimmune, Allmiral, Cabaletta Bio, and Novartis - May 21st, 2026 5:42 am
2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug - May 20th, 2026 2:38 pm
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading - May 19th, 2026 9:27 am
How The argenx (ENXTBR:ARGX) Narrative Is Shifting With Vyvgart Growth And Pipeline Uncertainty - May 14th, 2026 11:10 pm
Veeva Commercial Summit to Feature Biopharma's AI Successes and the Path to Agentic Commercial - May 14th, 2026 5:03 am
Is argenx SE (ARGX) Among the Most Promising Biotech Stocks to Buy? - May 13th, 2026 11:56 am
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up - May 12th, 2026 9:49 am
AbCellera Biologics Q1 Earnings Call Highlights - May 11th, 2026 5:05 pm
Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial - May 11th, 2026 4:00 am
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG - May 8th, 2026 3:20 pm
Argenx CEO Transition Frames Vision 2030 As FDA Decision Nears - May 8th, 2026 9:20 am
FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended - May 8th, 2026 4:07 am
Argenx Fends Off First-Quarter Seasonality, But Shares Defy Analysts' Bullish Views - May 7th, 2026 2:04 pm